$10.13 Million in Sales Expected for Roivant Sciences Ltd (NASDAQ:ROIV) This Quarter

Wall Street analysts forecast that Roivant Sciences Ltd (NASDAQ:ROIV) will announce $10.13 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Roivant Sciences’ earnings, with the lowest sales estimate coming in at $6.00 million and the highest estimate coming in at $14.27 million. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Roivant Sciences will report full-year sales of $36.99 million for the current financial year, with estimates ranging from $31.70 million to $50.54 million. For the next fiscal year, analysts forecast that the firm will post sales of $44.88 million, with estimates ranging from $8.40 million to $92.11 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Roivant Sciences.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Monday, November 15th. The company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.19. The firm had revenue of $13.99 million during the quarter, compared to analyst estimates of $5.30 million.

ROIV has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Roivant Sciences in a research note on Wednesday, December 15th. They issued a “buy” rating and a $15.00 target price for the company. HC Wainwright assumed coverage on shares of Roivant Sciences in a report on Monday, November 8th. They issued a “buy” rating and a $14.00 price target for the company. Truist assumed coverage on shares of Roivant Sciences in a report on Tuesday, October 26th. They issued a “buy” rating and a $15.00 price target for the company. Cowen assumed coverage on shares of Roivant Sciences in a report on Tuesday, October 26th. They issued an “outperform” rating for the company. Finally, Citigroup assumed coverage on shares of Roivant Sciences in a report on Wednesday, October 27th. They issued a “buy” rating and a $11.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Roivant Sciences has an average rating of “Buy” and an average target price of $13.00.

ROIV stock opened at $7.95 on Friday. Roivant Sciences has a one year low of $5.80 and a one year high of $16.76. The stock has a fifty day moving average price of $9.93.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

Recommended Story: Tariff

Get a free copy of the Zacks research report on Roivant Sciences (ROIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.